MX2010011101A - Conjugados de oligomero-propanamina sustituida con ariloxi. - Google Patents

Conjugados de oligomero-propanamina sustituida con ariloxi.

Info

Publication number
MX2010011101A
MX2010011101A MX2010011101A MX2010011101A MX2010011101A MX 2010011101 A MX2010011101 A MX 2010011101A MX 2010011101 A MX2010011101 A MX 2010011101A MX 2010011101 A MX2010011101 A MX 2010011101A MX 2010011101 A MX2010011101 A MX 2010011101A
Authority
MX
Mexico
Prior art keywords
oligomer
aryloxy
water
compound according
alkyl
Prior art date
Application number
MX2010011101A
Other languages
English (en)
Spanish (es)
Inventor
Jennifer Riggs-Sauthier
Franco J Duarte
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2010011101A publication Critical patent/MX2010011101A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2010011101A 2008-04-11 2009-04-13 Conjugados de oligomero-propanamina sustituida con ariloxi. MX2010011101A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12392908P 2008-04-11 2008-04-11
PCT/US2009/002285 WO2009126333A1 (en) 2008-04-11 2009-04-13 Oligomer-aryloxy-substituted propanamine conjugates

Publications (1)

Publication Number Publication Date
MX2010011101A true MX2010011101A (es) 2010-11-01

Family

ID=41016853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010011101A MX2010011101A (es) 2008-04-11 2009-04-13 Conjugados de oligomero-propanamina sustituida con ariloxi.

Country Status (10)

Country Link
US (1) US9233165B2 (https=)
EP (1) EP2265290B1 (https=)
JP (1) JP5543958B2 (https=)
KR (1) KR101680385B1 (https=)
CN (2) CN101998866A (https=)
AU (1) AU2009234322B2 (https=)
CA (1) CA2720760C (https=)
IL (1) IL208567A (https=)
MX (1) MX2010011101A (https=)
WO (1) WO2009126333A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226970B2 (en) 2010-02-22 2016-01-05 Nektar Therapeutics Oligomer modified diaromatic substituted compounds
WO2012088529A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-sunitinib conjugates
WO2012088522A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
CN106478376A (zh) * 2016-10-08 2017-03-08 贵州大学 一种4‑氟萘‑1‑醇的制备工艺

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE372762B (https=) * 1969-05-21 1975-01-13 Haessle Ab
JPS5123488A (https=) 1974-08-21 1976-02-25 Matsushita Electric Industrial Co Ltd
US4992540A (en) * 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5028703A (en) * 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
TR201907313T4 (tr) * 2003-05-23 2019-06-21 Nektar Therapeutics İki PEG zinciri içeren PEG türevleri.
US7947261B2 (en) * 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
EP2905033B1 (en) * 2003-12-16 2020-09-02 Nektar Therapeutics Monodisperse PEGylated naloxol compositions
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
DE602005016297D1 (de) * 2004-11-29 2009-10-08 Lilly Co Eli Antithrombotische diamide
MX2007009797A (es) 2005-02-14 2007-11-06 Combinatorx Inc Compuestos y sus usos.
WO2007109564A2 (en) * 2006-03-17 2007-09-27 University Of Massachusetts Yeast cell particles as oral delivery vehicles for antigens
WO2008112287A1 (en) * 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-beta blocker conjugates

Also Published As

Publication number Publication date
EP2265290B1 (en) 2014-06-04
IL208567A (en) 2015-11-30
CA2720760A1 (en) 2009-10-15
US20110071207A1 (en) 2011-03-24
WO2009126333A1 (en) 2009-10-15
KR101680385B1 (ko) 2016-11-28
AU2009234322A1 (en) 2009-10-15
EP2265290A1 (en) 2010-12-29
US9233165B2 (en) 2016-01-12
CN105566284A (zh) 2016-05-11
AU2009234322B2 (en) 2014-12-04
JP2011516551A (ja) 2011-05-26
CN101998866A (zh) 2011-03-30
KR20100132030A (ko) 2010-12-16
JP5543958B2 (ja) 2014-07-09
IL208567A0 (en) 2010-12-30
CA2720760C (en) 2016-10-11

Similar Documents

Publication Publication Date Title
EP2121031B1 (en) Oligomer-antihistamine conjugates
KR101539797B1 (ko) 올리고머-삼환계 콘쥬게이트
US10869933B2 (en) Oligomer-phenothiazine conjugates
US9314463B2 (en) Oligomer-diarylpiperazine conjugates
US10251959B2 (en) Oligomer-beta blocker conjugates
US9399033B2 (en) Oligomer-containing pyrrolidine compounds
US9233165B2 (en) Oligomer-aryloxy-substituted propanamine conjugates
US9168311B2 (en) Oligomer-dantrolene conjugates and related compounds
US9540330B2 (en) Oligomer-containing hydantoin compounds
US20110009446A1 (en) Oligomer-guanidine class conjugates

Legal Events

Date Code Title Description
FG Grant or registration